Drugs / SHR-A2102
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07414953 | Mar 2026 → Apr 2027 expected | lung cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05701709 | Apr 2023 → Aug 2025 overdue | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05735275 | Mar 2023 → Aug 2025 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07059221 | Jul 2025 → Mar 2027 expected | head and neck squamous cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06955390 | May → Dec 2025 overdue | cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06639347 | Nov 2024 → May 2027 expected | urothelial carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06589778 | Sep 2024 → Apr 2026 overdue | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06512051 | Jul 2024 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06474468 | Jun 2024 → Oct 2026 expected | esophageal cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06417554 | May 2024 → Jul 2027 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 212 trials · 1 met primary | ||||||
| Phase 2 | NCT07229729 | Nov 2025 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07175220 | Oct 2025 → Oct 2028 expected | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07041437 | Jun 2025 → Sep 2026 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06819319 | Jun 2025 → Dec 2026 expected | triple-negative breast carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06915142 | Apr 2025 → Dec 2026 expected | cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06895928 | Mar 2025 → Dec 2028 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06654440 | Nov 2024 → Aug 2025 overdue | female reproductive organ cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06649331 | Oct 2024 → Sep 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06547736 | Oct 2024 → Mar 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06433609 | Aug 2024 → Mar 2027 expected | breast cancer | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05076682 | Jun 2022 → Dec 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06879145 | Apr 2025 → Dec 2031 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07418749 | Mar 2026 → Dec 2027 expected | cervical cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07393542 | Feb 2026 → Sep 2027 expected | urothelial carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06738251 | Feb 2025 → Jul 2026 overdue | urothelial carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | Jiangsu HengRui Medicine Co., Ltd. | Results 恒瑞医药Nectin-4 ADC创新药SHR-A2102治疗经治晚期实体瘤I期研究荣登《柳叶刀·肿瘤学》 hengrui.com ↗
结果显示，SHR-A2102在经治晚期非小细胞肺癌（NSCLC）、乳腺癌等多个瘤种中展现出令人鼓舞的抗肿瘤活性与可管理的安全性特征，且不良反应谱与既往单甲基奥瑞他汀E（MMAE）类Nectin-4 ADC存在明显差异 1 。 |
| 2026-06-03 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ASCO口头报告｜恒瑞医药Nectin-4 ADC创新药SHR-A2102联合阿得贝利单抗围手术期治疗肌层浸润性膀胱癌研究结果重磅发布 hengrui.com ↗
北京时间5月30日，恒瑞医药自主研发的新型Nectin‑4 ADC创新药SHR‑A2102联合PD‑L1抑制剂阿得贝利单抗用于肌层浸润性膀胱癌（MIBC）围手术期治疗（SHR‑A2102‑303研究）II期阶段的初步研究结果重磅公布。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞医药Nectin-4 ADC创新药SHR-A2102治疗经治晚期实体瘤I期研究荣登《柳叶刀·肿瘤学》 hengrui.com ↗ |
| 2026-06-03 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ASCO口头报告｜恒瑞医药Nectin-4 ADC创新药SHR-A2102联合阿得贝利单抗围手术期治疗肌层浸润性膀胱癌研究结果重磅发布 hengrui.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-A2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05701709 ↗ |
| Modality | Other / unclassified | “novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102” NCT06433609 ↗ |
| Route | Intravenous | “SHR-A2102 was given intravenously.” NCT05701709 ↗ |